Genflow Biosciences Plc (LON: GENF) has appointed Gad Berdugo as Independent Non-Executive Chairman, a move intended to support the group’s next phase of corporate development and R&D expansion.
Berdugo brings extensive experience across biotechnology, capital markets and company building, with particular expertise in RNA-based therapeutics and lipid nanoparticle (LNP) delivery systems. He is currently Managing Partner at Explorium Capital LLC and has previously served as chief executive of EpiVax Oncology and chief business officer at Editas Medicine.
Genflow said the appointment is expected to help accelerate progress across its gene therapy programmes, with key data readouts anticipated in 2026. The company also sees the strengthened board leadership as an opportunity to deepen global engagement, enhance strategic execution and support long-term shareholder value creation.
Currently, Mr. Berdugo is the Managing Partner of Explorium Capital LLC, a U.S.-based strategic and financial advisory firm focusing on the global biotechnology sector. His most recent roles include:
· Co-Founder & CEO, EpiVax Oncology
· Vice-Chairman of the Board, Evexta Bio
· Chief Business Officer, Editas Medicine (NASDAQ: EDIT)
· Chief Business Officer, Nutcracker Therapeutics
He began his international career at Abbott Labs and Baxter, later becoming Life Sciences Sector Leader at Lazard Asset Management.
Mr. Berdugo also brings deep technical and market expertise in RNA-based therapeutics, including lipid nanoparticle (LNP) delivery, development, and manufacturing. This background will support Genflow as it advances its scientific platform, evaluates delivery technologies, and explores next-generation therapeutic approaches. His appointment further strengthens the Company’s presence in the United States and expands its capacity for global engagement.
He does not own any shares in the Company.
Dr. Eric Leire, Chief Executive Officer of Genflow, commented: “We are delighted to welcome Mr. Berdugo as Independent Non-Executive Chairman. His expertise in strategy, partnerships and financing as well as his deep experience with RNA-LNP technologies will be instrumental as we accelerate our programs and expand our global reach. We are equally pleased that Mrs. Tamara Joseph will continue her service on the Board, contributing her invaluable leadership, legal and governance expertise.”
Gad Berdugo added: “I am excited to join Genflow as the company is progressing to the next new phase of development, with key data readouts expected in 2026, strengthened intellectual property, and a sharpened strategic focus on high-potential programs. I look forward to working with the talented team and board to advance these innovative gene therapies, this is an ideal moment to contribute my expertise and help drive Genflow, and deliver long-term value for shareholders and patients.”
